Distribution of antiretroviral treatment through self-forming groups of patients in Tete province, Mozambique by Decroo, Tom et al.
IMPLEMENTATION AND OPERATIONAL RESEARCH:C LINICAL SCIENCE
Distribution of Antiretroviral Treatment Through
Self-Forming Groups of Patients in Tete
Province, Mozambique
Tom Decroo, MD,* Barbara Telfer, MPH,* Marc Biot, MD, MSc,* Jacob Maı ¨ke ´re ´, MD, MSc, PhD,†
Sergio Dezembro,* Luisa Isabel Cumba, MD,‡ Carla das Dores, MD,‡
Kathryn Chu, MD, MSc,§
k and Nathan Ford, MPH, PhD§¶
Background: As antiretroviral treatment cohorts continue to
expand, ensuring patient retention over time is an increasingly
important concern. This, together with capacity and human resource
constraints, has led to the consideration of out-of-clinic models for
the delivery of antiretroviral therapy (ART). In 2008, Me ´decins Sans
Frontie `res and the Provincial authorities launched a model of ART
distribution and adherence monitoring by community groups in Tete
Province, Mozambique.
Programme Approach: Patients who were stable on ART for
6 months were informed about the community ART group model and
invited to form groups. Group members had 4 key functions:
facilitate monthly ART distribution to other group members in the
community, provide adherence and social support, monitor outcomes,
and ensure each group member undergoes a clinical consultation at
least once every 6 months. Group members visit the health centre on
a rotational basis, such that each group member has contact with the
health service every 6 months.
Results: Between February 2008 and May 2010, 1384 members
were enrolled into 291 groups. Median follow-up time within a group
was 12.9 months (IQR 8.5–14.1). During this time, 83 (6%) were
transferred out, and of the 1301 patients still in community groups,
1269 (97.5%) were remaining in care, 30 (2%) had died, and 2 (0.2%)
were lost to follow-up.
Discussion: The Community ART Group model was initiated by
patients to improve access, patient retention, and decongest health
services. Early outcomes are highly satisfactory in terms of mortality
and retention in care, lending support to such out-of-clinic
approaches.
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retention, self-management
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INTRODUCTION
The number of people receiving antiretroviral therapy
(ART) in low-income countries continues to increase, with an
estimated 5 million people on treatment as of July 2010. As
treatment cohorts continue to expand and age, the question of
how to ensure that patients initiated on ART are supported to
remain in care is becoming an increasingly important concern.
A recent systematic review of programs in sub-Saharan Africa
reported that on average almost a third of patients were lost to
follow-up (LTFU) within 2 years of being initiated on to ART.
1
Several studies have indicated that practical challenges—
distance to services and transport costs, work responsibilities,
and family commitments—are associated with defaulting from
care.
2,3 Barriers at the health facility level such as long waiting
times, patient experience with the health system, stigma and
discrimination, and lack of social support and information for
adherence have also been reported as reasons for defaulting.
1
Thus, ensuring that ART services are accessible as close as
possible to the community is an important way to improve
access to and retention in care.
4–6
ART is a lifelong therapy, and the number of patients
entering treatment continues to increase, leading to concern
that conventional health systems will become increasingly
overwhelmed. The limited health workforce in high HIV
prevalence settings together with the need to provide ART at
the community level has led to consideration of out-of-clinic
models of care that would engage patients in essential tasks
including ART distribution and peer support for adherence and
social support.
7
Mozambique faces many problems common to high
HIV burden countries in southern Africa. The government
began providing ART in 2003, but the dire lack of human
resources and infrastructure for heath care provision has
limited coverage: in 2007, it was estimated that only around
one third of people in need of ARTwere receiving treatment,
8
whereas overall, only around half of the population have
access to an acceptable level of health care.
9 Access to and
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country due to distances to health facility, transportation costs,
and long waiting times.
10
In 2008, in collaboration with patients and local health
authorities, Me ´decins Sans Frontie `res (MSF) piloted a model
of ART distribution and adherence monitoring by community
groups to supplement the conventional mode of ART delivery
in health clinics and hospitals. The model was initially
proposed during problem-solving discussions between coun-
selors and ART patients as a potentialway to improveretention
while giving patients greater responsibility for certain aspects
of service provision.
In this article, we describe the implementation of the
community ART group (CAG) model and report preliminary
outcomes.
PROGRAM DESCRIPTION
Project Setting
Tete Province lies in central Mozambique and borders
Malawi, Zambia, and Zimbabwe. Approximately 85% of the
province’s 1.8 million inhabitants live in rural areas. Adult
HIV prevalence is estimated at 13%.
11 MSF has been sup-
porting the health authorities in Tete Province since 2002 in the
implementation and scale-up of HIV care and treatment. ART
provision began in May 2003 at Tete Provincial hospital and
was decentralized to selected peripheral health centres in
2006.
12 By mid-2010, 1 quarter of health facilities in Tete
Province (28 of 105) were authorized to initiate ART. Despite
signiﬁcant progress in increasing access to ART services
through decentralization of HIV care and task shifting, about
1 in 5 ART patients in Tete are LTFU, and at least half of
those LTFU are estimated to be dead.
12
Stakeholder Consultation
Group discussions were conducted between patients and
counselors at health facilities supported by MSF. Patients
reported that the main barriers to ARTaccess and retention on
ART were transport costs and perceived stigmatization by
attending health facilities and time lost waiting in long queues
at clinics, often just for reﬁlls.
Ministry of Health Guidelines state that patients stable
on ARTonly need a clinical consultation once every 6 months,
but ART supplies can only be given monthly. The practical
consequence is that patients often travel long distances to pick
up medications every month. The CAG approach was
proposed in consultation with patients as a way for patients
to utilize existing social networks and pool resources to reduce
the individual requirement to travel and queue at health centers
each month for ART prescriptions and provide mutual support
for adherence and social needs.
Participating Clinics and Group Formation
CAGs were established in 12 health facilities in 6
districts (Chiuta, Changara, Moatize, Tete City, Cahora
Bassa, and Mutarara) of Tete Province. The estimated
population of the 6 districts with CAGs was 900,666. As of
May 2010, 11,052 people were active on ART, among whom
half (5772) were attending health centers at which CAGs
were established.
13
Participating health facilities were required to have the
following minimum package of services: HIV counseling and
testing, a clinician authorized to prescribe ART, a guaranteed
supply of ART and opportunistic infection prophylaxis, and
transport for CD4 samples and results.
At the group level, members had 4 key practical
functions as follows: to collect and distribute ARTeach month
to group members in the community; to provide community-
based adherence support and treatment outcome monitoring;
to establish a community-based treatment social support net-
work; and to ensure each group member undergoes a clinical
consultation at least once every 6 months. The group elected
a group leader who facilitates monthly group meetings,
conducts monthly pill counts, and monitors group attendance.
CAGs were promoted in clinic waiting areas, during
consultation and counseling sessions and through information
distributed within the community. To join a group, patients
needed to be clinically stable on ART for a minimum of
6 months and have CD4 $200 cells per cubic millimeter.
Interested patients were advised to form groups of up to 6,
elect a group leader, and present to their nearest clinic for
eligibility assessment by a clinician. Counselors trained newly
formed groups in the approach and in the roles and responsi-
bilities of patients in a group, conducted monthly monitoring
of groups of group representatives, and conducted group
counseling and education sessions.
Community ART Groups
Each month, a group representative visits the nearest
health facility to collect medicines for the group. Every member
is expected to serve as the group representative on a rotational
basis such that each patient has contact with a health centre
every 6 months. Group members could still visit the health
centre at any other time, for any reason, if required.
A group meeting is held in the community before each
clinic visit, and the designated group leader counts each mem-
bers’ pills (adherence check). Any new signs or symptoms,
adherence problems, or intention to relocate to another area
or interrupt treatment are discussed and documented for each
patient on the group-held group monitoring form. The group
chooses a member who will represent and report on the
group and collect medications at health facility level, for
that month. The patients give their appointment cards to the
group representative to take them to the health facility.
At facility level, the group representative discusses each
group member with a counselor or clinician, covering such
issues as adherence (self-report and pill count), clinical status,
and any action to be taken such as requesting a patient to
attend the health facility for consultation, bloods, or adherence
counseling. The group monitoring form is jointly reviewed.
The group representative then meets with a clinician who
prescribes ART and prophylactic drugs for each group
member. The patient-held appointment cards are updated
by the clinician or counselor. The group representative also
undergoes a clinical consultation at this visit. The group
representative then returns to the community and distributes
ART and other medicines to each patient, returns the patient-
e40 | www.jaids.com q 2011 Lippincott Williams & Wilkins
Decroo et al J Acquir Immune Deﬁc Syndr   Volume 56, Number 2, February 1, 2011heldappointmentcards,and,wherenecessary,requestsagroup
member to go to the health facility for follow-up.
All members from different CAGs linked to the same
health facility are invited 6 monthly for a group session at the
health facility or in the community. Health education and
information updates on topics such as CAG dynamic, adher-
ence, when to come for an unplanned consultation, tubercu-
losis, prevention of mother to child transmission, opportunistic
infections, and treatment issues are provided. A blood sample
for CD4 is taken at the end of the session for all who are
present (Table 1).
Monitoring and Evaluation
Three paper-based tools are used to monitor CAGs: the
national patient-held appointment card, the clinic-based
patient ﬁle, and a group monitoring form.
The patient-held appointment cards are given to the
grouprepresentativebefore thehealth facility visitand brought
TABLE 1. Summary of CAG Implementation Steps
Consult stakeholders Hold group discussions with patients,
health authorities, and health facility staff
Select project sites Select sites according to, for example, size of ART cohort
(urban sites), geographical isolation of surrounding population
(rural sites), and whether a facility had the following features:
HIV counseling and testing
Transport for CD4 samples & results
A clinician authorized to prescribe ART, follow patients, draw blood
from patients for CD4 counts, and familiar with procedures for CAG project
A person to manage the groups (counselor, clinician, other)
A person to dispense ART and a secure supply of ART and
opportunistic prophylaxis
Prepare health facilities to manage CAGs Design a guideline with health authorities, tailored to reality of each facility
Train facility staff in the CAG model and their ﬂexible roles and responsibilities
Promote CAG model as voluntary option to
conventional care for stable ART patients
Provide patients with information on CAGs in health facility waiting areas,
during consultations and counseling sessions
Ask patients who attended the health facilities to inform other ART patients
known to them in their local area, about CAGs
Request patients to form groups of a maximum of 6, and elect a group leader
Request groups to present to a facility to be screening for eligibility to join CAGs
Screen interested ART patients Eligibility criteria:
Followed on ART at least 6 months
Taking ﬁrst line ART with weight greater than 25 kg
Taking an alternative ﬁrst line regimen containing Efavirenz with weight . 40 kg
Be clinically stable and without any active WHO Stage III or IV clinical condition
Have a CD4 count in last three months greater than 200 mm
3
Screening: By clinician or counsellor. Documentation in patient ﬁle
Train group members once screened Train and educate group members in the CAG model, the practical functions of
group members, and the responsibilities of the group leader and group representative
Open 2 copies of the group monitoring form, 1 for the group, 1 for the facility
Every month groups meet in community,
a group representative attends the health
facility to report on the group and collect
antiretrovirals, to distribute in the
community
Groups meet in community each month to count pills, monitor adherence and
outcomes, update the group monitoring form, and elect a group representative
The group representative for the month attends the facility to report on the group,
collect antiretrovirals for each group member, and to have an individual clinical consult
Clinicians prescribe ART each month for individual patients in standard manner. The group
monitoring form is updated
Group representative distributes ART to members in community
Patients can attend the facility at any other time they need, for any reason
Monitor patients and ART groups and
provide ongoing support and quality
improvement
Monthly group meeting in community (intragroup monitoring)
Monthly feedback from group representative to facility (group-facility monitoring)
Monthly update of information on ART group monitoring form
Patient ﬁle, consultation registers, and other standard monitoring tools updated
Monthly standard reports to health authorities and analysis of database
Every 6 months all group members attend the facility for a group meeting/training,
and to have blood collected for CD4 count
Activities conducted to audit the quality of functioning of CAGs, such as follow-up of
patients who died, were LTFU or have adherence problems
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The next CAG reﬁll dates are updated on appointment cards
and then returned to each group member in the community
along with a 1-month supply of ART.
Paper-based patient ﬁles are kept in all health facilities
and contain essential information on each patient: unique
patient ID, name, contact details, age, sex, clinical history, CD4
results, clinical consultation ﬁndings, medications prescribed,
adherence and counseling information, and other details.
The group monitoring form includes information on
ART prescription and pill counts for all group members and
acts as a group-speciﬁc cohort register. The group monitoring
form contains basic background information including patient
identiﬁcation number, sex, age, date initiated ART, CD4 at
ART initiation, count and date of last CD4, monthly dates of
ART collection, monthly pill counts, date of next consultation,
and a basic health check. One side of the form is updated by
the group representative and group members (pill count and
patient signature of approval) each month. The group repre-
sentative takes this form (along with the patient-held cards)
to the facility each month, where it is reviewed with clinic
staff and updated with information such as number of ART
dispensed to the group representative for each patient, date to
nextcollect ART for thegroup and new CD4 results. Acopyof
the group monitoring form is held at the clinic.
Information from the 3 monitoring tools are encoded in
an electronic database (Excel) by a trained data manager to
evaluate the following program-level information: demo-
graphic and other baseline information, date of ARTinitiation,
CD4 count at ART initiation, date each patient joined ART
group, name of ART group, dates of ART distribution, dates of
6 monthly CD4 blood collection and individual consultation,
CD4 results, pill count at time of each ART distribution,
number of pills dispensed, and standard patient outcomes.
Data are analyzed each month to track enrollment, patient
follow-up and outcomes, undertake data cleaning, and
generate aggregate health centre outcome reports for CAGs.
Patient Consent and Protections
CAGs were started as a programatic response as solution
to respond to the many obstacles patients encountered in
accessing their monthly treatment and to alleviate over-
burdened health centers. A number of basic securities were put
in place to ensure voluntary participation and patient data
protection. From the beginning, participation in CAG care has
been voluntary. At the start of the program, basic information
about the CAG approach, including eligibility criteria and
roles and responsibilities of group members was made
available in the local language through information sessions
in health facility waiting areas and in discussion with patients
who had defaulted from care. At any time, patients in CAG
care could opt and return to standard care and follow-up. No
ﬁnancial or material incentive was provided. The CAG
electronic database is password-protected and locked and
stored in a secure room according to normal standards. The
program was formally approved by local health authorities.
A number of processes were established to ensure the
proper functioning of the groups. CAG members were
encouraged to report to their clinician or counsellor any
serious problem experienced within a group, such as diversion
or non-receipt of antiretrovirals. Regular meetings were held
with members at community and health facility level to
identify any problems and counsellors conducted ad hoc audits
through brief structured interviews with group members at
facility level. All adverse events such as death or defaulting
were investigated and documented.
RESULTS
The ﬁrst CAG was established in February 2008. By
May 31, 2010, 1384 members had been enrolled into 291
groups (Table 2). Group members had been on ART for
a median of 22.3 months (interquartile range: 9.7–34.2) at
enrollment. Median age at enrollment into a group was 36
years, and the majority (70%) were female, consistent with
demographic characteristics of adults in conventional ART
care in Tete province
12 Median follow-up time within a group
was 12.9 months (interquartile range: 8.5–14.1) (Table 3).
A review of documentation and meetings with facility
staff and CAG leaders conﬁrmed that all doses of ART were
collected from the facility and deliveredto patients. Adherence
monitoring was successful, with 92% of patients (1173 of
1269 members as 31 May 2010) had their last 2 pill counts
recorded correctly on the group monitoring form.
Adverse outcomes were reviewed for all patients. Of the
1384 patients who had enrolled into a CAG, 83 (6%) had been
transferred either back to conventional care or to another
treatment centre, in general due to patients changing place of
residence. Of the remaining 1301 patients, 1269 (97.5%) were
remaining in care, 30 (2%) had died, and 2 (0.2%) were LTFU.
Of 48 members that returned to standard care, 27 left due to
change of residence, 3 due to poor adherence to ART, 12 for
medical reasons, and 6 for social reasons unrelated to the
group. Among the 30 CAG member who died, 3 died of acute,
unknown circumstances at home, whereas the remainder had
all had at least 1 clinical consultation related to their illness
leading to death: 21 deaths due to HIV-related causes, the
remaining 6 due to non–HIV-related illness. The 2 instances of
defaulting were due to change of residence and social reasons
unrelated to CAGs or their care.
Finally, in terms of workload reduction, staff at health
facilities reported that CAGs resulted in an approximately
4-fold reduction in consultations among patients in CAGs.
DISCUSSION
The CAG approach was designed together with patients
in response to patient reported barriers to retention on
treatment, and as such was a highly acceptable alternative
mode of service delivery for stable ART patients. For patients,
CAGs represent a way to decrease the ﬁnancial and economic/
social costs of their treatment, take greater responsibility for the
management of their ownhealth,andbeactive partners inhealth
care delivery. Beyond simply reducing transport costs, the
groups provides a means of encouraging greater patient
responsibility for their own health and building and reinforcing
social networks and peer support, which have been identiﬁed as
important ways to support adherence to treatment.
14,15
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reported in the literature, in which rates of LTFU at 12 months
range from 1.2% to 26%.
1 For Mozambique, the national
average rate of defaulting at 12 months is 15%.
16 However, the
data presented are programatic data and as such are subject to a
number of limitations common to observational studies that
threaten the validity and generalizability of the ﬁndings.
In particular, survivorship bias resulting from the eligibility
criteria that requires patients to be clinically stable and to have
been on ART for 6 months before being able to join the
program may limit generalizability. Nevertheless, the current
low rate of defaulting and mortality in this program suggests
that the approach described herein has clear potential in sup-
porting long-term ART management, at least for stable patients.
Around 5 million people are currently receiving ART in
developing countries, and another 10 million people are
currently estimated to be in need of treatment.
17 The growing
number of patients on ART is not, however, being met by
a commensurate increase in the numbers of clinics and clinic
staff. High HIV burden settings are usually chronically under
resourced to meet current needs: it is estimated that a 7-fold
increase in health personnel is required in Mozambique to
meet the health needs of the population.
18
For ART delivery to be sustainable and successful in the
longterm,thereisaneedfor modelsofcarethatseparateclinical
patientmanagement (whichrequirestrainedhealthworkers)and
the dispensing of medicines (which does not), and address
patient-reported barriers to treatment access and retention.
A shift from acute to chronic care implies a greater emphasis
on self-management of disease outside of a clinical setting, with
patients assuming an active and informed role in managing
physical, psychological, and social aspects of health.
19
In Western countries, chronic disease self-management
programs are accepted as a way to improve patient outcomes
and reduce the burden on healthcare systems for a range of
chronic diseases including asthma,
20 diabetes,
21 arthritis,
22
chronic obstructive pulmonary disease,
23 and cancer.
24 Non-
physician-led approaches such as repeat prescriptions
25 and
patient held records
26 have been found to be of beneﬁt to
patients and health services. For HIV care, the concept of
chronic disease self-management has been proposed for over
a decade but has been largely conﬁned to adherence support.
27
More recently, out-of-clinic approaches to ART care have been
piloted as away to decongest overburdened health services and
simplify treatment for patients. A recent cluster randomized
trial in Uganda found that home-based ART delivery was
equivalent to facility-based ART delivery in terms of survival
and virological suppression.
28 In Tanzania, community-based
volunteers and trained medical workers support mobile drug
distribution by reﬁlling prescriptions in the community, and
this has anecdotally led to reduced LTFU.
29 In western Kenya,
people living with HIV/AIDS havebeen trained and salaried to
provide follow-up to clinically stable HIV patients in their
communities and distribute ART and prophylaxis for
opportunistic infections.
30 The positive early outcomes of
the CAG approach presented here lend support to such out-of-
clinic approaches.
Improving retention in care is just one challenge to
health services in high-HIV prevalence settings. Substantial
attrition has also been reported among patients diagnosed HIV
positive and awaiting ART initiation, both in Mozambique
31
and elsewhere.
32 Innovative approaches are also needed across
the care cascade from HIV diagnosis to long-term retention.
The future reﬁnement of the CAG approach in Mozambique
will include reﬂection on how this approach can support the
health service and improving outcomes across the treatment
cascade. For example, many CAGs have members who are not
yet eligible for ARTwho join monthly group meetings in the
community and beneﬁt from the social support and education.
Inthisway, theCAG model may alsohelp tominimize pre-ART
defaulting, an issue of growing concern in ART programs in
southern Africa.
32 Another challenge lies in the need to develop
adapted approaches for vulnerable subgroups as children,
adolescents, pregnant woman, commercial sex workers, and
HIV/TB-coinfected patients. Finally, the CAG program requires
long-term follow-up and formal evaluation comprising both
qualitative and quantitative approaches to determine its effec-
tiveness, acceptability, sustainability, and generalizability.
Although there remains an urgent need to continue to
enroll patients onto ART as a medical priority, program
implementers must also begin to take the long view, including
from the patients’ perspective. HIV/AIDS is a chronic disease
TABLE 2. Baseline Characteristics of CAG Patients
Category Value
Total 1384
Number of facilities with CAGs 12
Number of groups 291
Average number per group 5
Female, number (%) 968 (70)
Age at enrollment (years), median (IQR) 36 (30–43)
CD4 count at ART initiation, median (IQR)* 176 cells/mm
3 (105–247)
Months on ART pre-CAG, median (IQR) 22.3 (9.7–34.2)
*Data missing for 86 patients.
IQR, interquartile range.
TABLE 3. Outcomes at May 31, 2010, of CAG Patients, Tete
Province, Mozambique
Outcome Value
Total 1384
Months in CAGs, median (IQR) 12.9 (8.5–14.1)
Died: n, % (95% CI) 30, 2.2% (1.5% to 3.1%)
LTFU: n, % (95% CI) 2, 0.1% (0% to 0.5%)
Transferred out to other health
facility: n, % (95% CI)
35, 2.5% (1.8% to 3.5%)
Transferred back to conventional
care: n, % (95% CI)
48, 3.5% (2.6% to 4.6%)
Active in CAG: n, % (95% CI) 1269, 91.7% (90.1% to 93.1%)
CD4 gain since initiation,
median (IQR)*
478.5 cells/mm
3 (313.5–642)
*Data available for 78% (836) of patients: patients in CAGs at least 9 months and
who had a CD4 in last 6 months.
CI, conﬁdence interval; IQR, interquartile range.
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initiated on ART in resource-limited settings can expect to live
around 30 years on treatment.
33 The long-term management
of ART in resource-limited settings will require out-of-clinic
solutions, with patient-clinic partnerships, in particular for
patients who are stable on ART. Community-based approaches
represent an important dimension in this approach.
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